Overview

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

Status:
Completed
Trial end date:
2018-09-20
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab